Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether the (a) availability and (b) levels of use of tan-enhancing products containing Melanotan II is being considered in the development of the forthcoming cancer plan.

The Government is taking steps to prevent, diagnose, and treat cancers more quickly, including skin cancers. The forthcoming National Cancer Plan will cover the entirety of the cancer pathway from referral and diagnosis to treatment and ongoing care. It will set out how we will improve outcomes for cancer patients, including by speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately driving up this country’s cancer survival rates. We will publish the National Cancer Plan in the new year to reduce the number of lives lost to cancer over the next 10 years.

We received over 11,000 responses to our call for evidence from individuals, professionals, and organisations, and we are reviewing the submissions from skin cancer partners. While no formal assessment has been made of the availability and levels of use of tan-enhancing products containing Melanotan II, respondents shared concerns about tanning products and their potential links to cancer, particularly melanoma. Our expansive engagement will allow the National Cancer Plan to have patients at its heart.

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for the regulation of medicinal products and medical devices in the United Kingdom. Although tanning is not considered to be a medical purpose, injectable products containing Melanotan I or Melanotan II have been determined as medicinal products due to their similarity to the authorised medicine Scenesse.

In relation to nasal sprays containing Melanotan I or Melanotan II, there are no equivalent authorised medicines and in the absence of medicinal claims, they are not regarded as medicinal products.

Medicinal products must hold a relevant Marketing Authorisation to be legally sold and supplied in the UK. This also guarantees that the medicines have been tested for conformity with strict standards of quality, safety, and efficacy.

The MHRA takes action when a medicinal product without appropriate authorisations is identified.